Kenneth Mahaffey, MD
Cardiovascular Disease · Stanford, CANPI 1659455707
Payments from drug & device makers
Across 268 payments — averaging $3176.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$466K
- Novo Nordisk$92K
- E.r. Squibb & Sons, L.L.C.$81K
- Quidel Corporation$40K
- CSL Behring$33K
- Bayer$27K
- plus $113K from 14 others
Across 53 payments — averaging $2349.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$89K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
- Sanofi US Services Inc.$17K
What the payments were for
- Consulting fees$360,65481%
- Speaking & faculty fees$21,7635%
- Travel & lodging$59,06613%
- Food & beverage$5,0531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 118 | $466,441 |
| Novo Nordisk | 2 | $91,681 |
| E.r. Squibb & Sons, L.L.C. | 26 | $80,527 |
| Quidel Corporation | 6 | $40,120 |
| CSL Behring | 16 | $32,536 |
| Bayer | 22 | $26,979 |
| Eli Lilly | 6 | $26,600 |
| Novo Nordisk AS | 8 | $20,545 |
| Modernatx, Inc. | 24 | $14,500 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $13,320 |
| AstraZeneca | 7 | $11,902 |
| Johnson & Johnson | 3 | $6,072 |
| Novartis | 3 | $5,020 |
| Regeneron | 1 | $3,570 |
| Boehringer Ingelheim International GmbH | 1 | $3,500 |
| Janssen Global Services, LLC | 3 | $3,273 |
| Janssen Scientific Affairs, LLC | 4 | $1,988 |
| Sanofi US Services Inc. | 3 | $1,690 |
| Astrazeneca UK Limited | 7 | $1,058 |
| Gilead | 1 | $98 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$33,760
- INVOKANA$29,836
- Kerendia$18,213
- EPANOVA$12,823
- Non-Covered$5,363
- Moderna Covid-19 Vaccine$4,000
- PRALUENT$3,570
- EFPEGLENATIDE$1,690
- XARELTO$443
- ENTRESTO$101
How this compares
$851,422 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Praluent PenAlirocumab | 13 | $6,044 |
| Ezetimibe | 18 | $809 |
| Metoprolol Succinate | 21 | $409 |
| Atorvastatin Calcium | 29 | $324 |
| ClopidogrelClopidogrel Bisulfate | 14 | $163 |
| Rosuvastatin Calcium | 16 | $103 |
| Losartan Potassium | 31 | $80 |
| Diltiazem 24hr ErDiltiazem Hcl | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Yu-Ping WangStanford$3.8M
- Wilber SuStanford$3M
- Rajesh DashStanford$2.9M
- John CookeStanford$1.2M
- Abha KhandelwalStanford$1.1M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.